Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Chinese patients with advanced pNET
NCT02842749Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2016
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in Pancreatic neuroendocrine tumor (PanNET), sponsored by Novartis. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 years. Started Mar 2016; status: completed.
02
Drugs
everolimus
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02842749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842749.